These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 16035152)

  • 1. Clinical relevance of tumor markers for the control of chemotherapy.
    Finek J; Holubec L; Topolcan O; Salvet J; Pikner R; Holdenrieder S; Stieber P; Lamerz R; Holubec Sen L; Svobodova S; Visokai V; Helmichova E
    Anticancer Res; 2005; 25(3A):1655-8. PubMed ID: 16035152
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of Ki-67 proliferation and apoptotic index before, during and after neoadjuvant chemotherapy for primary breast cancer.
    Burcombe R; Wilson GD; Dowsett M; Khan I; Richman PI; Daley F; Detre S; Makris A
    Breast Cancer Res; 2006; 8(3):R31. PubMed ID: 16790076
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dynamic monitoring of cardio-specific markers and markers of thyroid gland function in cancer patients--a pilot study.
    Holubec L; Topolcan O; Finek J; Salvet J; Svoboda T; Svobodova S; Mrazkova P; Ludvikova M
    Anticancer Res; 2007; 27(4A):1883-6. PubMed ID: 17649788
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tumor markers as useful predictors of survival rate after exploratory laparotomy for liver malignancies.
    Liska V; Holubec L; Treska V; Skalicky T; Sutnar A; Topolcan O; Kormunda S; Finek J
    Anticancer Res; 2007; 27(4A):1887-91. PubMed ID: 17649789
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical biomarkers of kinase activity: examples from EGFR inhibition trials.
    Krause M; Baumann M
    Cancer Metastasis Rev; 2008 Sep; 27(3):387-402. PubMed ID: 18427731
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Changes of thymidine kinase (TK) during adjuvant and palliative chemotherapy.
    Topolcan O; Holubec L; Finek J; Stieber P; Holdenrieder S; Lamerz R; Holubec Sen L; Svobodova S; Visokai V; Lipska L
    Anticancer Res; 2005; 25(3A):1831-3. PubMed ID: 16033109
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [The effect of the microenvironment of head and neck cancers on tumor progression].
    Lukits J
    Magy Onkol; 2009 Mar; 53(1):51-9. PubMed ID: 19318327
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Serum tumor markers at exocrine adenocarcinoma of pancreas].
    Holubec L; Finek J; Topolcan O; Svobodová S
    Cas Lek Cesk; 2005; 144(2):86-8; discussion 89. PubMed ID: 15807292
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gene expression profiles of breast cancer obtained from core cut biopsies before neoadjuvant docetaxel, adriamycin, and cyclophoshamide chemotherapy correlate with routine prognostic markers and could be used to identify predictive signatures.
    Rody A; Karn T; Gätje R; Kourtis K; Minckwitz G; Loibl S; Munnes M; Ruckhäberle E; Holtrich U; Kaufmann M; Ahr A
    Zentralbl Gynakol; 2006 Apr; 128(2):76-81. PubMed ID: 16673249
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Markers of cellular adhesion in diagnosis and therapy control of colorectal carcinoma.
    Holubec L; Topolcan O; Finek J; Holdenrieder S; Stieber P; Pesta M; Pikner R; Holubec Sen L; Sutnar A; Liska V; Svobodova S; Visokai V; Kormunda S
    Anticancer Res; 2005; 25(3A):1597-601. PubMed ID: 16033066
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Post chemotherapy RPLND in patients with elevated markers: current concepts and clinical outcome.
    Beck SD; Foster RS; Bihrle R; Einhorn LH; Donohue JP
    Urol Clin North Am; 2007 May; 34(2):219-25; abstract ix-x. PubMed ID: 17484926
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biochemical markers for monitoring response to therapy: evidence for higher bone specificity by a novel marker compared with routine markers.
    Leeming DJ; Hegele A; Byrjalsen I; Hofmann R; Qvist P; Karsdal MA; Schrader AJ; Wagner R; Olbert P
    Cancer Epidemiol Biomarkers Prev; 2008 May; 17(5):1269-76. PubMed ID: 18483350
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum CYFRA 21-1 in patients with invasive bladder cancer and its relevance as a tumor marker during chemotherapy.
    Andreadis C; Touloupidis S; Galaktidou G; Kortsaris AH; Boutis A; Mouratidou D
    J Urol; 2005 Nov; 174(5):1771-5; discussion 1775-6. PubMed ID: 16217281
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ProGRP and NSE in therapy monitoring in patients with small cell lung cancer.
    Wójcik E; Kulpa JK; Sas-Korczyńska B; Korzeniowski S; Jakubowicz J
    Anticancer Res; 2008; 28(5B):3027-33. PubMed ID: 19031951
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic significance of changes in CA 15-3 serum levels during chemotherapy in metastatic breast cancer patients.
    Tampellini M; Berruti A; Bitossi R; Gorzegno G; Alabiso I; Bottini A; Farris A; Donadio M; Sarobba MG; Manzin E; Durando A; Defabiani E; De Matteis A; Ardine M; Castiglione F; Danese S; Bertone E; Alabiso O; Massobrio M; Dogliotti L
    Breast Cancer Res Treat; 2006 Aug; 98(3):241-8. PubMed ID: 16670941
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dynamic enhanced MRI predicts chemosensitivity in breast cancer patients.
    Nagashima T; Sakakibara M; Nakamura R; Arai M; Kadowaki M; Kazama T; Nakatani Y; Koda K; Miyazaki M
    Eur J Radiol; 2006 Nov; 60(2):270-4. PubMed ID: 16926079
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A proof-of-principle clinical trial of bexarotene in patients with non-small cell lung cancer.
    Dragnev KH; Petty WJ; Shah SJ; Lewis LD; Black CC; Memoli V; Nugent WC; Hermann T; Negro-Vilar A; Rigas JR; Dmitrovsky E
    Clin Cancer Res; 2007 Mar; 13(6):1794-800. PubMed ID: 17363535
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Tumor markers--personal experience. How to read time course of some values and tumor marker doubling time].
    Takahashi Y; Mai M
    Gan To Kagaku Ryoho; 1991 Apr; 18(4):665-70. PubMed ID: 2012408
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Uses and abuses of tumor markers in the diagnosis, monitoring, and treatment of primary and metastatic breast cancer.
    Henry NL; Hayes DF
    Oncologist; 2006 Jun; 11(6):541-52. PubMed ID: 16794234
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Genomic markers and anticancer chemotherapy].
    Nishiyama M
    Gan To Kagaku Ryoho; 2008 Feb; 35(2):194-9. PubMed ID: 18281756
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.